Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1623 1673 1693 4100
This examiner grants 62% of resolved cases
Dale R. Miller works in Tech Center 4100 and Art Unit 1623, where he has resolved 729 cases. His allowance rate is 62.4%, indicating a fair chance of success for applicants. The median days to allowance is 954, which is a relatively standard timeframe for prosecution in this tech center and helps in managing client expectations.
The interview lift is 17.5%, suggesting that direct dialogue is a beneficial strategy for improving results. This lift means that the probability of allowance increases when an interview is held, compared to the 62.4% baseline rate. In a practice with 729 resolved cases, this trend is a reliable indicator that Miller is open to resolving issues through verbal discussion in Art Unit 1623.
The 954-day median pendency is an important consideration for planning prosecution cycles. Combined with a 62.4% allowance rate, the data suggests a balanced environment for applicants. The 17.5% interview lift provides practitioners with a clear tactical option to improve their outcomes and potentially resolve cases more efficiently in Tech Center 4100.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18289431 | COMPOSITIONS AND METHODS FOR SIMPLE SAMPLE EXTRACTION | Non-Final OA | Abbott Molecular Inc. |
| 18633908 | THERAPEUTIC COMPOUNDS | Non-Final OA | Regents of the University of Minnesota |
| 18291956 | COMPOSITION FOR CARING FOR KERATIN MATERIALS | Non-Final OA | L'OREAL |
| 18569169 | A NON-THERAPEUTIC COSMETIC METHOD FOR REDUCING WRINKLES ON A SKIN SURFACE | Final Rejection | L'Oreal |
| 18194374 | METHOD FOR TREATING OBESITY AND/OR HYPERTENSION | Final Rejection | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION |
| 18663736 | COMPOSITION FOR REDUCING BODY FAT CONTAINING GALLOCATECHIN GALLATE AND ISOQUERCITRIN | Non-Final OA | AMOREPACIFIC CORPORATION |
| 18697116 | PROGRAMMABLE SELECTIVE ACYLATION OF POLYOLS | Non-Final OA | Nanyang Technological University |
| 18396181 | BIODEGRADABLE LIPIDS AND FORMULATIONS FOR INTRAMUSCULAR, IN VITRO, AND EX VIVO TRANSFECTION OF MRNA | Non-Final OA | Children's Medical Center Corporation |
| 18718915 | CARDIAC STEROID DERIVATIVES | Non-Final OA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. |
| 18717355 | ANTIFUNGAL COMPOUND, COMPOSITION AND USES THEREOF | Non-Final OA | VERSITECH LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy